The genesis and evolution of acute myeloid leukemia stem cells in the microenvironment: From biology to therapeutic targeting

Yongfeng Chen, Jing Li, Linglong Xu, Mihnea-Alexandru Gâman and Zhenyou Zou

© The Author(s) 2022

Acute myeloid leukemia (AML) is a hematological malignancy characterized by cytogenetic and genomic alterations. Up to now, combination chemotherapy remains the standard treatment for leukemia. However, many individuals diagnosed with AML develop chemotherapeutic resistance and relapse. Recently, it has been pointed out that leukemic stem cells (LSCs) are the fundamental cause of drug resistance and AML relapse. LSCs only account for a small subpopulation of all leukemic cells, but possess stem cell properties, including a self-renewal capacity and a multi-directional differentiation potential. LSCs reside in a mostly quiescent state and are insensitive to chemotherapeutic agents. When LSCs reside in a bone marrow microenvironment (BMM) favorable to their survival, they engage into a steady, continuous clonal evolution to better adapt to the action of chemotherapy. Most chemotherapeutic drugs can only eliminate LSC-derived clones, reducing the number of leukemic cells in the BM to a normal range in order to achieve complete remission (CR). LSCs hidden in the BM niche can hardly be targeted or eradicated, leading to drug resistance and AML relapse. Understanding the relationship between LSCs, the BMM, and the generation and evolution laws of LSCs can facilitate the development of effective therapeutic targets and increase the efficiency of LSCs elimination in AML.

Cell Death Discovery (2022) 8:397; https://doi.org/10.1038/s41420-022-01193-0

FACTS

- Abnormal BM niche may be involved in the pathogenesis of AML.
- The BMM exerts a selective pressure for the clonal evolution in leukemia, and oxidative stress may represent another one.
- The protection from BMM and the clonal evolution of LSC may responsible for drug resistance in leukemia.
- Target BMM may be a potential therapeutic strategy for leukemia treatment.

OPEN QUESTIONS

- What is the exact role and mechanism of BMM in leukemogenesis?
- How to avoid damage to normal hematopoietic and hematopoietic supporting cells while eradicating leukemia cells?
- How to effectively repair the abnormal BMM?
- How to effectively unblock the protection of BMM on AML cells?

INTRODUCTION

Acute myeloid leukemia (AML) is a group of highly heterogeneous clonal diseases. The constant accumulation of acquired somatic mutations in hematopoietic stem cells (HSCs) is the primary pathogenic mechanism of AML. Recently, the emergence of novel chemotherapeutic drugs and the progress of HSC transplantation have considerably improved the remission rate and disease-free survival of AML patients. However, the high relapse rate of AML, which is largely attributed to the residual leukemic stem cells (LSCs), remains an unsettled thorny issue. LSCs represent a subpopulation of malignant cells with unlimited self-renewal capacity and multi-directional differentiation potential. Despite representing a small proportion of all leukemic cells (approximately 0.1–1%), LSCs are considered the origin of leukemia and the primary cause of relapse after treatment, as well as of drug resistance [1]. LSCs are closely related to the bone marrow microenvironment (BMM). The BMM not only provides a habitat for LSCs but also offers the support for the survival and development of LSCs while alleviating the pressure imposed by chemotherapy on LSCs. This feature of the BMM can lead to the generation of dominant clones, resulting in leukemia relapse and drug resistance. Therefore, an in-depth investigation of the relationship between LSCs and the BMM, as well as the generation...
and evolution laws of LSCs, will facilitate the understanding of the pathogenesis and drug resistance mechanism of AML.

ABNORMAL BM NICHE INVOLVEMENT IN THE PATHOGENESIS OF AML

The BM is the principal hematopoietic organ consisting of HSCs and the hematopoietic microenvironment. The latter is also known as the stem cell niche, which consists of bone marrow stromal cells (BMSCs) and extracellular matrix (ECM). Normal hematopoiesis is the process whereby HSCs self-renew and the progenitor cells proliferate and differentiate in the BM microenvironment.

BMSCs are integral components of the hematopoietic microenvironment and play an indispensable role in maintaining the stability, homing, proliferation, and differentiation of HSCs [3]. Accumulated evidence demonstrates that the dysfunction of BMSCs impairs the BMM, thereby affecting normal hematopoiesis. Besides, the dysfunction of BMSCs will trigger and promote the development of malignant hematological diseases. Many studies have reported that AML is linked with a reduction in BMSCs. In most AML cases, cytogenetic abnormalities of BMSCs are usually found [4–7]. Besides, BMSCs derived from AML patients may exhibit molecular and functional alterations, e.g., higher senescence, decreased proliferation, reduced clonogenic potential, impaired in vitro osteogenic and adipogenic differentiation, imbalanced regulation of endogenous hematopoiesis, and increased support of leukemia growth [8–11].

Recently, several research groups have used animal models to explore the role of BM in leukemia. According to Raaijmakers et al., selectively knocking out Dicer1 (a gene required for RNA and microRNA processing) in mesenchymal osteoprogenitors impaired osteoblast differentiation both in vitro and in vivo. In mouse models, the loss of Dicer1 in osteoprogenitors induced an evident hematopoietic disorder, increased apoptosis, and proliferation of hematopoietic stem and progenitor cell (HSPC). These knockout animals exhibited key features of human myelodysplastic syndromes (MDS), including the propensity to develop AML [12]. A study by Kode et al. demonstrated that activating mutations of β-catenin in mouse osteoblasts stimulated the expression of Notch ligand jagged 1, which subsequently altered the differentiation potential of myeloid and lymphoid progenitors through the activation of Notch signaling, and ultimately led to the development of AML [13]. These findings suggested that functional abnormalities caused by genetic mutations in BMSCs may play a crucial role in leukemogenesis. Yilmaz et al. implanted HSCs with tumor suppressor gene phosphatase and tensin homolog (PTEN) knocked out into irradiated recipient mice. These PTEN-deficient HSCs gradually depleted over time after a brief multilineage differentiation, while no evidence of myeloproliferation or development of leukemia was discovered in any recipient mice. In contrast, the implantation of PTEN-deficient whole bone marrow cells led to myeloproliferative progression to leukemia/lymphoma. These results suggested that BMSCs may play a more critical role in the malignant transformation of normal hematopoietic cells into leukemia cells [14]. The occurrence of donor cell leukemia in clinical AML cases further indicates that the hematopoietic microenvironment may be involved in the pathology of AML. However, the concrete mechanism underlying the hematopoietic microenvironment deterioration is still poorly understood. Recent evidence suggested that oxidative stress may play a key role: Huang et al. investigated the effect of iron overload (IO) on BMSCs in MDS and AML patients. The results showed that IO could promote the ROS generation and apoptosis in BMSCs, decrease expression of hematopoietic regulation-related genes such as VEGFA, CXCL12, and TGF-β1, and activate the Wnt/β-catenin signaling pathway, and it was supposed that these alterations may be associated with the MDS progression [15]. Li et al. showed that daunorubicin (DNR) treatment led to senescence of mouse BMSCs, increased ROS production, as well as mitochondrial dysfunction. When oxidatively damaged BMSCs were co-cultured with HSCs in vitro, these stromal cells generated more ROS, leading to increased genomic instability in HSCs [16]. In addition, BMSCs injury might also lead to impaired immune surveillance and dysregulated cytokine secretion, disrupted BM homeostasis, and ultimately led to abnormal proliferation of hematopoietic cells, all of which may be potential causes of malignant transformation of hematopoietic cells [16]. However, the exact role and mechanism of BMM in leukemogenesis still need to be elucidated by more extensive and in-depth studies.

ORIGINS AND GENERATION OF LSC

It is generally believed that LSC result from mutation accumulation in HSC. Long-term HSCs are capable of self-renewal. Long-term exposure to carcinogens will cause the accumulation of genetic mutations in these HSCs, increasing the risk of malignant transformation of these cells. Hope et al. performed continuous tracking of the transplanted LSCs and highlighted that LSCs are not functionally homogeneous but, similarly to the normal HSC compartment, comprised distinct hierarchically arranged LSC classes. This finding supported the hypothesis that LSCs originate from normal HSCs [17]. In another study, Cozzio et al. adopted transgenic technology to analyze three types of cells with different differentiation grades: HSCs, common myeloid progenitors, and the lineal descendent granulocytic/monocytic-restricted progenitors. These three types of cells could survive and proliferate in vitro after mixed lineage leukemia (MLL) fusion genes were introduced. The mice could be successfully transplanted with these cells, which induced leukemia at the same speed [18]. Thus, it was speculated that LSCs have a wide variety of sources. LSCs may be derived from HSCs and progenitor cells that are earlier in the development stage and also from leukemia progenitor cells that are more mature.

According to the AML two-hit model, two major types of genetic mutations play a pivotal role in the pathogenesis of AML. Type I genetic mutation involves the tyrosine kinases in the signal transduction pathway, including the signaling molecules FMS-like tyrosine kinase-3 (FLT3), stem cell factor receptor (c-Kit), and break point cluster region-abelson (BCR-ABL). Persistently activated tyrosine kinases confer special benefits for the proliferation and survival of hematopoietic precursor cells [19]. Type II mutation involves disrupting transcription factors or transcriptional coactivators, such as acute myeloid leukemia-1 transcription factor/eight-twenty-one corepressor (AML1/ETO), mixed-lineage leukemia/ALL1 fused gene from chromosome 9 protein (MLL/AF9), and promyelocytic leukemia/retinoic acid receptor α (PML/RARA) fusion gene. These abnormal changes can lead to disorders of differentiation, maturation, and apoptosis of hematopoietic progenitor cells (HPC) [20]. In mouse models, when genetic abnormalities of type I occurred alone, chronic myeloid leukemia (CML)-like changes were noted; when genetic abnormalities of type II occurred alone, MDS-like changes were noted. Under normal situations, leukemia occurs when these two types of genetic abnormalities occur simultaneously [21]. So far, it remains uncertain how the two types of genetic abnormalities work synergistically.

Recently, a large number of studies have shown that AML patients carry repeated mutations of many important epigenetic mediators. Among them, mutations of genes related to DNA methylation are most common, including DNA methyltransferase 3A (DNMT3A) and isocitrato dehydrogenase 1 and 2 (IDH1/2) mutations. Genetic modeling of individual epigenetic factors has shown that most of these mutations will affect the HSC compartment and alter hematopoietic differentiation, in some cases leading to myelodysplasia, stem cell expansion, or other preleukemic conditions [22–24]. Besides, mutations of other
epigenetic modifiers, such as additional sex combs-like (ASXL1) and enhancer of zeste homolog 2 (EZH2), also play an important role in the occurrence of AML (Table 1). However, epigenetic mutations alone are not sufficient to transform HSCs, indicating that sequential acquisition of mutations is required [25]. In a recent study, Uckelmann et al. reported that in Npm1c/Dnmt3a mutant knock-in mice, a model of AML development, the use of a small molecule (VTP-50469) can reverse the self-renewal of preleukemic HSCs, indicating that epigenetic modifiers are key to transform HSCs, indicating that current epigenetic therapy in a preventative setting [26].

### Table 1. Common epigenetic modifier mutations in AML.

| Classification  | Modifier | Biological activity                                                                 | Frequency   | Ref.  |
|-----------------|---------|--------------------------------------------------------------------------------------|-------------|-------|
| DNA methylation | DNMT3A  | Majority of DNMT3A mutations are heterozygous missense mutations causing premature truncation of R882. The interaction between R882 and PRC1 leads to downregulation of hematopoietic differentiation genes, inducing aberrant proliferation of HSPC. | 12–35%      | [104, 105] |
| TET2           |         | TET2 catalyzes the conversion of 5mc to 5-hmC, resulting in demethylation. Loss of TET2 function can increase methylation and reduce the expression of mitotic checkpoint proteins MAD2 and CDC20, leading to CIN. | 10%         | [104, 106] |
| IDH1/2         |         | The interaction between IDH1 and TET2 leads to increased methylation and impaired DNA damage repair functions. | 20%         | [104] |
| MLL            |         | The most common form of MLL gene rearrangement is chromosomal translocation, which is usually the translocation fusion between MLL-N and the C-terminal domain of translocation partner gene (TPG) to form fusion genes. The formation of MLL fusion protein induces overexpression of HOXA9 and Meis1 genes, which contributes to the over proliferation of immature HSPC. | 5–10%       | [107, 108] |
| Histone modification | EZH2 | EZH2 controls expression of genes involved in stem cell maintenance and differentiation. Down-regulation of EZH2 inhibited apoptosis, affected MAD2 and CDC20 expression, and promoted CIN in AML cells. | 4%          | [106, 109] |
| CBP            |         | CBP alterations lead to HAT inactivation, which may result in faulty histone acetylation and abnormally activated gene expression, promoting leukemia transformation. | 2.5%        | [110–112] |
| HDAC           |         | HDAC antagonizes the acetylation of HAT and inhibits the expression of tumor suppressor genes, while the down-regulation of HDAC can enhance the activity of some tumor suppressor genes and promote their transcription and translation. | 2%          | [113, 114] |
| ASXL1          |         | ASXL1 mutations resulted in increased stabilization of BAP1 and its recruitment to chromatin and the induction of an oncogenic transcriptional program. | 20%         | [104, 115] |

Abbreviations: SmC 5-methylcytosine, S-hmc 5-hydroxymethylcytosine, ASXL1 Additional sex comb-like 1, BAP1 BRCA1-associated protein 1, CBP CREB-binding protein, CDC20 Cell-division cycle protein 20, CIN Chromosome instability, EZH2 Enhancer of zeste homolog 2, HAT Histone acetyltransferases, HDAC Histone deacetylases, HOXA9 Homeobox A9, MAD2 Mitotic Arrest Deficient 2, Meis1 Meis homeobox 1, PRC1 Polycomb Repressive Complex 1, TET2 Ten-eleven translocation methylcytosine dioxygenase 2.

**EVALUATION OF LSC**

Recent studies have shown that AML cell populations at relapse may have evolved from either the dominant clonal or minor subclonal cell populations present at diagnosis, accompanied by the potential activation of additional mutations. AML cells adapt to the environment by steady, continuous clonal evolution and better survive under chemotherapy pressure [27–30].

The clonal evolution in leukemia is a multi-step, dynamical evolutionary process. Corces-Zimmerman et al. analyzed the persistence of preleukemic mutations in patients in remission. It was discovered that mutations in preleukemia were present in CD34+ progenitor cells and various mature cells, indicating that preleukemic HSCs can survive the induction chemotherapy, thereby confirming these cells as a reservoir for the reevolution of relapsed disease [31]. Moreover, they tentatively proposed several patterns of clonal evolution leading to AML relapse based on the existing whole genome sequencing results: (1) treatment refractory primary disease, (2) further evolution of a dominant clone present at diagnosis, (3) outgrowth of a subclone present at diagnosis; (4) further evolution of disease from a preleukemic HSC [31]. Miles et al. employed single-cell DNA sequencing to analyze the samples from 123 patients with myeloid malignancies to determine the clonal features of myeloid malignancies. The results showed that AML is dominated by a small number of clones. Among different types of genetic mutations, epigenetic mutations usually occur at the early stage of leukemogenesis, and these mutations tend to occur simultaneously. In contrast, mutations of genes related to the cell signaling pathways occur much later, which are mainly found in distinct subclones, consistent with increased clonal diversity. Besides, it was found that increased clonal diversity in AML did not coincide with the difference in the number of mutations within the largest clone, suggesting that increased mutational burden within a clone is not the primary driver of clonal dominance [32].

A major distinctive feature of cancer cells is their genetic instability. Cancer cells may evolve along paths under different selective pressures to gain survival and development advantages, a primary reason for continuous clonal evolution in leukemia. The BMH exerts a selective pressure for the clonal evolution in leukemia. It is not only a shelter for leukemic cells but also supports the survival and development of leukemia cells by interacting with them, thereby relieving the chemotherapeutic pressure and promoting the generation of dominant clones (section 4). Elevated reactive oxygen species (ROS) levels are hallmark features of leukemia cells [33, 34], and oxidative stress induced by high level of ROS may represent another selective pressure for the clonal evolution in leukemia. The sources of ROS levels in AML cells are complex and diverse. Among them, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) and mitochondrial electron transport chain (mtETC) are considered to be the main sources of ROS in leukemia cells [35]. However, Hole et al. found that AML cells treated with NOX inhibitors could more effectively inhibit the production of superoxide compared with mtETC inhibitors and mitochondrial ROS scavengers, therefore suggesting that ROS in AML cells is
It was reported that, oncogenic kinases like BCR-ABL1, FLT3-internal tandem duplication (ITD), or c-KIT can promote the generation of endogenous ROS by increasing the activities of RAC GTPases or membrane-bound NOX [37–40]. In addition, chemotherapy and chronic inflammation can also increase ROS generation, thereby elevating oxidative stress [37, 41, 42]. Although quiescent AML LSCs have a strong ability to maintain the redox balance, they still suffer from oxidative damage to DNA caused by high ROS levels. Such damage increases genomic instability and drives the genetic evolution of LSCs under the synergistic action of the leukemic microenvironment, from which LSCs gain a competitive advantage [35, 43] (Fig. 1). Further investigations are needed to reveal the specific mechanism by which LSCs evolve genetically.

INTERACTIONS BETWEEN AML CELLS AND THE BMM

The interactions between LSCs and the microenvironment are fundamental to survival, therapeutic resistance, and relapse of leukemia. In the BMM, hypoxia induces the synthesis of hypoxia-inducible factor-1α (HIF-1α), which plays a key role in cell migration and survival. In human AML cells, HIF-1α knockdown leads to increased apoptosis and impaired cell engraftment [44]. Furthermore, hypoxia can also upregulate C-X-C chemokine receptor type 4 (CXCR4) expression in AML cells, the cognate receptor of chemokine ligand 12 (CXCL12), and promote CXCL12 expression in BMSCs via HIF-1α [45, 46]. Relying upon the interaction between CXCR4 and CXCL12, as well as the adhesion effect mediated by other surface adhesion molecules, AML cells dwell in the BM niches to maintain their survival [44–47]. Besides, the interaction between BMM and AML cell can also lead to the activation of phosphatidylinositol-3-kinase/protein kinase B (PI3K/AKT), wingless-related integration site (Wnt), NOTCH, and other signal pathways, which play key roles in the regulation of AML cells’ maintenance, proliferation, and differentiation (Fig. 2). A series of in vitro and in vivo experiments confirmed that AML cells can remodel the BMM by inducing the abnormal proliferation and differentiation of BM mesenchymal stem and progenitor cells (MSPCs), thereby favoring disease development and progression [48, 49]. Evidence suggests that AML cell-derived exosomes can stimulate the expression of Dickkopf-1 (DKK1), thereby inducing downregulation of HSC-supporting factors in BMSCs and reducing their ability to support normal hematopoiesis [50]. Furthermore, AML cell-derived exosomes can also downregulate critical retention factors, such as stem cell factor (SCF) and CXCL12, leading to the mobilization of HSPC out of the BM [51]. In a recent study, Scoville et al. found that human AML blasts can activate the transcription factor aryl hydrocarbon receptor (AHR) pathway and induce mirt-29b expression in natural killer (NK) cells, thereby impairing NK cell maturation and function, which may be one of the important mechanisms underlying AML cells’ immune escape [52].

In severely hypoxic BM tissues, leukemic cells exhibit the strong adaptive ability and promote angiogenesis via multiple mechanisms. Such a capacity is needed to meet the demand for oxygen and nutrients in rapidly growing leukemic cells. Hypoxia has been reported to promote AML cells’ upregulation of transcription and expression of several angiogenic factors, such as vascular endothelial growth factor (VEGF), thus increasing the angiogenic activity of endothelial cells [53, 54]. Angiopoietin/Tyrosine Kinase With Immunoglobulin-like And Epidermal Growth Factor-like...
Domain-2 (Ang/Tie-2) axis is another signaling pathway that is significantly associated with angiogenesis [55]. Tie-2 receptor is always overexpressed in AML cells, which promotes angiogenesis via interaction with Ang-1 [56]. The Ang-1/Tie-2 interactions also facilitates the adhesion of AML cells to BM niche, and helps to maintain the quiescent and anti-apoptotic state of LSC in BM niche [57, 58] (Fig. 2). In vitro experiments showed that Tie-2-blocking antibodies had a growth inhibitory effect on human AML cells co-cultured with microvascular endothelial cells [58]. However, the application of antiangiogenic drugs is often found ineffective in clinical studies, indicating that the deterioration of BM is not simply due to angiogenesis. Recently, Passaro and colleagues reported that in human AML patient-derived xenografts, significant abnormalities in the bone marrow vasculature were observed. The engrafted AML not only promoted angiogenesis but also increased the permeability of blood vessels. Further analysis showed that the increased vascular permeability was associated with hypoxia-induced increases in ROS and NO. Cytarabine (AraC) treatment achieved only transient remission, and it was supposed that this may be relevant to the increase of vascular permeability, since increased vascular permeability not only leads to poor drug delivery, but also favors the tumor growth and enhances metastatic potential. The combination of nitric oxide synthase inhibitors and chemotherapy successfully restored normal vasculature and delayed leukemia, leading the way to combine leukemia-niche therapies in clinical trials [59].

Fatty acid metabolism is the main metabolic pathway for AML cell survival in the adipocyte-rich BM [60]. The study by Shafat et al. found that AML cells can alter adipocyte metabolic processes, inducing lipolysis of triglyceride to fatty acid, and the fatty acid was then transferred to AML cells to fuel FAO, thereby promoting the survival and proliferation of AML cells [61]. Tunneling nanotubes (TNTs), or membrane nanotubes, are an important means of communication between eukaryotes [62]. Recent studies have shown that AML cells can propel mitochondrial transfer from BMSCs to AML cells via TNTs under the stimulation of ROS, which generated from NOX. As a result, more energy is generated for survival of AML cells by mitochondrial OXPHOS. However, such a phenomenon was not observed in HSCs that derive energy primarily from anaerobic glycolysis [63]. These studies demonstrated that AML cells acquire conspicuous survival benefits by interacting with BMSCs.
TARGETED THERAPY FOR AML

LSCs usually reside in a quiescent state, that is, the G0 phase, when the LSCs replicate slowly but have an unlimited self-renewal capacity. This biological characteristic of LSC make it insensitive to the cytotoxicity of the conventional cell cycle-targeting chemotherapy. Besides, the expression of multi-drug resistance proteins in LSCs results in poor clinical outcomes. In recent years, the advancement of both biomedical technology as well as the understanding of AML drug resistance mechanisms strongly promote the development of AML-targeted drugs. Drugs targeting AML cell surface antigens, mutant genes, and intracellular signaling pathways have become the current research trend and is therefore an ideal target to inhibit pro-survival signaling in AML cells. Among NOX family members, NOX1, NOX2, and NOX4 are expressed in human CD34+ hematopoietic progenitor cells [64, 65]. NOX2 inhibitors have been reported to induce reduction of intracellular ROS in FLT3-ITD AML cells, inhibition of downstream growth and survival pathways of FLT3, and increased apoptosis associated with induction of mitochondrial ROS and restoration of p38MAPK [66]. Setanaxib, an inhibitor with anti-NOX1 and NOX4 functions, has anti-proliferative effects on both FLT3-ITD-positive and negative AML cells, and has strong synergistic effects with cytotoxic drugs anthracyclines such as daunorubicin. This anti-proliferative effect may be mediated by amplification of oxidative stress signaling by promoting ROS production from sources other than NOX [67]. It was reported that a variety of chemotherapeutic drugs such as daunorubicin, cytarabine, and decitabine can also induce apoptosis in leukemia cells via ROS generation [68–70]. However, high levels of ROS inevitably cause oxidative damage to hematopoietic and hematopoietic supporting cells while eliminating leukemia cells.

Targeting the weaknesses in the metabolism of leukemia cells has attracted much attention in recent years. Fatty acid metabolism is the main metabolic pathway for AML cells to maintain survival, and drug-resistant LSCs have a higher FAO rate, suggesting that FAO is related to the drug resistance of LSCs [71]. However, intervention using the FAO inhibitor-avocatin-B was ineffective. Further investigation showed that glucose uptake and glycolysis were increased while inhibiting the FAO in AML cells, which promoted AML cell survival [60]. This finding suggested that targeting a single metabolic pathway has limitations as leukemic cells may escape through metabolic adaptation. Similarly, although the combination of Bcl-2 inhibitor venetoclax and azacitidine (ven/aza) inhibited OXPHOS in vivo and resulted in an effective eradication of LSCs [72, 73], ven/aza failed to eradicate LSCs in relapsed/refractory (R/R) patients, suggesting that metabolic properties had altered. Metabolomic analysis revealed that nicotinamide metabolism was elevated in relapsed LSCs, which activated amino acid metabolism and fatty acid oxidation to drive OXPHOS, and therefore avoided the cytotoxicity of ven/aza treatment [74, 75]. Recently, several research teams started to use nicotinamide phosphoribosyltransferase (NAMPT) as a new intervention. NAMPT is the rate-limiting enzyme in nicotinamide metabolism, and its application can selectively eradicate R/R LSC [74, 76]. These findings suggested that targeting metabolic weaknesses in AML cells may be an effective strategy.

Hypoxia is an important feature of the leukemia microenvironment and also an ideal target in AML therapy. In the hypoxic environment, the maintenance of neutral pH represents a key survival mechanism for leukemic cells. In the hypoxic environment, Carbonic Anhydrases IX and XII (CA IX/XII) function as transmembrane proteins that mediate intracellular pH value regulation, which is critical for leukemic cell survival, because maintaining a neutral pH represents a key survival mechanism for

| Targeting the surface antigens | NCT | Drug | Target | Patient population | Phase |
|-------------------------------|-----|------|--------|-------------------|-------|
| NCT03386513                  | IMGN632 | CD123 | Patients in whom CD123 can still be detected after receiving CD123 targeted drug treatment. | Phase 2 |
| NCT04342962                  | Tagraxofusp | CD123 | CD123+ relapsed adult AML patients | Phase 2 |
| NCT03867682                  | Lintuzumab | CD33 | Adult AML patients | Phase 2 |
| NCT04435691                  | Magrolimab | CD47 | Adult AML patients | Phase 2 |
| NCT03647800                  | APVO436 | CD123xCD3 | Adult AML and MDS patients | Phase 1 |
| NCT04582864                  | Flotuzumab | CD123xCD3 | Relapsed adult AML and MDS patients | Phase 2 |
| NCT03224819                  | AMG673 | CD33xCD3 | Adult R/R AML patients | Early phase |

| Targeting the mutant genes | NCT | Drug | Target | Patient population | Phase |
|----------------------------|-----|------|--------|-------------------|-------|
| NCT05024552                 | Gilteritinib | FLT3 | Adult R/R AML subjects with FLT3 mutations | Phase 1 |
| NCT03258931                 | Crenolanib | FLT3 | Newly diagnosed AML subjects with FLT3 mutations | Phase 3 |
| NCT03793478                 | Quizartinib | FLT3 | Pediatric R/R AML subjects with FLT3-ITD mutations | Phase 1 |
| NCT03575302                 | Azacitidine | DNMT3A | Non-elderly adult patients with AML | Phase 2 |
| NCT03844815                 | Decitabine | DNMT3A | Adult AML patients | Phase 1 |
| NCT04493164                 | Ivosidenib | IDH1/2 | Adult AML patients with IDH1 mutations | Phase 2 |
| NCT04203316                 | Enasidenib | IDH1/2 | 2–18 years R/R AML patients | Phase 2 |
| NCT03843528                 | Vorinostat | HDAC | Childhood myeloid malignancies | Phase 1 |

| Targeting the intracellular signaling pathways | NCT | Drug | Target | Patient population | Phase |
|------------------------------------------------|-----|------|--------|-------------------|-------|
| NCT04173585                                 | Bortezomib | NF-κB | Adult R/R AML patients | Phase 2 |
| NCT04655391                                 | Glasdegib | Hedgehog | Adult patients with relapsed AML post alloHCT | Phase 1 |
| NCT04562792                                 | Daunorubicin | Wnt | 1–21 Years R/R ALL and AML patients | Phase 2 |

**Table 2.** Ongoing clinical trials evaluating novel targeted agents for AML.
tumor cells in hypoxia [77]. The study by Chen et al. recently showed that dual CA IX/XII inhibitor FC531 can significantly reduce the pH level and induce apoptosis in AML cells in vitro with a synergistic effect with cytarabine. Furthermore, FC531 exhibited anti-leukemia effect in single-agent mode or in combination with cytarabine in vivo, which significantly improved the survival rate of AML mice [77]. TH-302 is a 2-nitroimidazole-linked prodrug that can be activated under hypoxia to generate potent cytotoxin bromo-isophosphoramide mustard (Br-iPM). In vitro experiments showed that TH-302 could inhibit the proliferation of AML cells and promote cell apoptosis by reducing the expression of HIF-1α. Additionally, in vivo experiments demonstrated that TH-302 could effectively prevent disease progression in AML mice and prolong mouse life expectancy [78, 79]. Moreover, TH-302 showed synergistic anti-leukemia effects in the FLT3-ITD AML model when combined with the tyrosine kinase inhibitor – Sorafenib [79]. It should be emphasized that the protection and repair of BM are as crucial as eliminating leukemia cells. In addition to the aforementioned repair of the BM vasculature, the restoration of redox balance is also a hot topic of current concern. Theoretically, scavenging excessively high levels of ROS with antioxidants should foster the repair of BM, thereby boosting the restoration of normal hematopoiesis. However, the use of antioxidants is not recommended clinically because malignant cells may also be protected. Several recent studies have shown that a variety of natural compounds, such as curcumin, quercetin, and resveratrol could protect normal cells from oxidative damage, exhibited excellent anti-leukemia effects, and synergized well with chemotherapy drugs, suggesting that natural antioxidants may have broad application prospects in clinical adjuvant therapy [80–84]. Notably, malignant niches are frequently coupled with inflammatory responses, however, the impact of inflammation on hematopoietic microenvironment homeostasis is poorly understood. Recently, an in vivo and in vitro study by Habbel et al. confirmed that AML cells could secrete inflammatory cytokines and activate the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathways in both AML blasts and BMMSCs, thereby increasing the ROS generation and AML proliferation. Blockade of this inflammatory response signaling pathway resulted in the suppression of AML cells, suggesting that improving the hematopoietic microenvironment by inhibiting the inflammatory response is essential to amplify the anti-leukemia effect [85]. Blocking the connection between AML cells and BMM and unblocking the protection of BMM on AML cells are both critical for eliminating leukemia cells. It was demonstrated that the application of anti-CD44, anti-CD82, and anti-CD98 monoclonal antibodies could block the adhesion between the microenvironment and AML cells, thereby inhibiting the survival of AML cells [86–88]. The CXCL12/CXCR4 axis is an important mechanism regulating the interaction between the microenvironment and AML cells. CXCR4 inhibitors, such as plerixafor, BL-8040, and LY2510924, could disrupt the chemotaxis mediated by the CXCL12/CXCR4 axis and dislodge the leukemic cells from their protective BM niches to increase the sensitivity of leukemia cells to chemotherapy [89–91]. However, one major defect of inhibiting CXCL12-CXCR4 interaction is the release of a large number of leukemic cells into the peripheral blood. In that case, the potential of leukemic cells infiltrating extramedullary organs will be enhanced. At present, nearly all open-label clinical trials using CXCR4 inhibitors as chemosensitizers involve the combination of the CXCR4 inhibitors and different chemotherapeutic drugs to increase the possibility of the activated leukemic cells being killed [92, 93].

CONCLUSION

BMM is not only the place where LSCs are generated, but also serves as a sanctuary for these malignant cells and provides support for their clonal evolution, reinforcing its involvement in the occurrence of drug resistance and recurrence of leukemia. Drug resistance mechanisms of leukemia mediated by BMM are highly complex. Various factors, including the adhesion between the leukemic cells and the microenvironment, signal transduction, and gene expression regulation, are involved, which form a complex regulatory network. The key components of the network may be new targets for leukemia treatment. Therapies targeting the interactions between BMM and leukemic cells are new strategies in the management AML, which are also the hotspots for research on the drug resistance mechanism of leukemia. However, the existing studies have some limitations, i.e., most are in vitro studies and cannot fully mimic the BMM under pathological conditions. Neither can such studies realistically reproduce the clonal evolution of leukemia in the BMM. Therefore, it is hard to precisely depict the real inner relationship between clonal evolution, heterogeneity, and drug resistance of AML. Another urgent problem is that the selectivity of targeted drugs needs to be further improved. BMM harbors leukemic cells and normal HSCs as well. Targeted drugs with poor selectivity may adversely affect the protective effect of the BMM on HSCs or even cause direct harm to HSCs, resulting in adverse reactions such as BM suppression. Therefore, constant optimization and more efforts are necessary in these fields. It is believed that in the near future, with the emergence of more perfect leukemia models and the development of new generation of analysis technology, the law of leukemia occurrence and development will be more deeply recognized, thus facilitating the precise treatment of leukemia.

DATA AVAILABILITY

Data sharing not applicable to this article as no datasets were generated or analyzed during this study.

REFERENCES

1. Jiang Y, Xu P, Yao D, Chen X, Dai H. CD33, CD96 and death associated protein kinase (DAPK) expression are associated with the survival rate and/or response to the chemotherapy in the patients with acute myeloid leukemia (AML). Med Sci Monit. 2017;23:1725–32.
2. Chen Y, Liang Y, Luo X, Hu Q. Oxidative resistance of leukemic stem cells and oxidative damage to hematopoietic stem cells under pro-oxidative therapy. Cell Death Dis. 2020;11:291.
3. Granéli C, Thorfve A, Ruetschi U, Brisby H, Thomsen P, Lindahl A, et al. Novel markers of osteogenic and adipogenic differentiation of human bone marrow stromal cells identified using a quantitative proteomics approach. Stem Cell Res. 2014;12:153–65.
4. Forte D, García-Fernández M, Sánchez-Aguilera A, Stavropoulos V, Fielding C, Martín-Pérez D, et al. Bone marrow mesenchymal stem cells support acute myeloid leukemia bioenergetics and enhance antioxidant defense and escape from chemotherapy. Cell Metab. 2020;32:829–43.e9.
5. Huang JC, Basu SK, Zhao X, Chien S, Fang M, Oehler VG, et al. Mesenchymal stromal cells derived from acute myeloid leukemia bone marrow exhibit aberrant cytogenetics and cytokine elaboration. Blood Cancer J. 2015;5:e302.
6. Kouvidi E, Stratigi A, Batsali A, Mavroudi I, Mastrodemou S, Ximeri M, et al. Cyto genetic evaluation of mesenchymal stem/stromal cells from patients with myelodysplasia syndromes at different time-points during ex vivo expansion. Leuk Res. 2016;43:24–32.
7. Blau O, Hofmann WK, Baldus CD, Thiel G, Serbent V, Schumann E, et al. Chemosensitizing aberrations in bone marrow mesenchymal stroma cells from patients with myelodysplastic syndrome and acute myeloblastic leukemia. Exp Hematol. 2007;35:221–9.
8. Pievani A, Donsante S, Tomasoni C, Corsi A, Dazzi F, Biondi A, et al. Acute myeloid leukemia shapes the bone marrow stromal niche in vivo. Haematologi ca. 2021;106:865–70.
9. Blau O, Baldus CD, Hofmann WK, Thiel G, Nolte F, Burmeister T, et al. Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts. Blood 2011;118:5583–92.
Kim JA, Shim JS, Lee GY, Yim HW, Kim TM, Kim M, et al. Microenvironmental remodeling as a parameter and prognostic factor of heterogeneous leukemogenesis in acute myelogenous leukemia. Cancer Res. 2015;75:2222–22.

11. Weickert MT, Hecker JS, Buck MC, Schreck C, Vrijsen J, Schieman M, et al. Bone marrow stromal cells from MDS and AML patients show increased adipogenic potential with reduced Delta-like-1 expression. Sci Rep. 2021;11:15944.

12. Rajasekharav MR, Mehnerey S, Guo S, Zhang S, Kobayashi T, Schoonderma J, et al. Bone progenitor dysfunction induces myelosuppression and secondary leukaemia. Nature 2010;464:852–7.

13. Kode A, Manavalan JS, Mosialou I, Bhagat G, Rathinam CV, Luo N, et al. Leukemogenesis induced by an activating β-catenin mutation in osteoblasts. Nature 2014;506:240–4.

14. Yilmaz OH, Valdez R, Thiesen BK, Guo W, Ferguson DO, Wu H, et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 2006;441:745–82.

15. Huang L, Liu Z, Liu H, Ding K, Mi F, Xiang C, et al. Iron overload impairs bone marrow mesenchymal stem cells from higher-risk MDS patients by regulating the ROS-related Bmp-2/catenin pathway. Stem Cells Int. 2020;2020:8855308.

16. Li Y, Yue Z, Dong X, Liu Q, Liu Z, Li H, et al. Mitochondrial dysfunction and oxidative stress in bone marrow stromal cells induced by daunorubicin leads to DNA damage in hematopoietic free cells. Free Radic Biol Med. 2016;106:211–21.

17. Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukaemic stem cell classes that differ in self-renewal capacity. Nat Immunol. 2004;5:738–43.

18. Cozzi A, Passegué E, Ayton PM, Karsunky H, Cleary ML, Weissman IL. Similar MM-associated leukaemia arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev. 2003;17:3029–35.

19. Zhao X, Liu HQ, Wang LN, Yang L, Liu XL. Current and emerging molecular and epigenetic disease entities in acute myeloid leukemia and a critical assessment of their therapeutic modalities. Semin Cancer Biol. 2020;S1044-579X:30246.

20. Lim HP. Integrative genomic and molecular characterisation of newly identified refractory pediatric acute myeloid leukemia. Leuk Res. 2018;65:20 –579X:30246.

21. Kurosawa S, Doki N, Hino Y, Sakaguchi M, Fukushima K, Shingai N, et al. Iron overload impairs bone marrow mesenchymal stromal cells from higher-risk MDS patients by regulating the ROS-related Wnt/β-catenin pathway. Haematologica 2012;97:966–74.

22. Park DJ, Kwon A, Cho BS, Kim HJ, Hwang KA, Kim M, et al. Characteristics of MLL-associated leukemias arising from self-renewing stem cells and short-lived Delta-like-1 expressing myeloid progenitors. Genes Dev. 2003;17:3029–35.

23. Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014;506:240–41.

24. Miles LA, Bowman RL, Merlinsky TR, Csete IS, Ooi AT, Durruthy-Durruthy R, et al. Coordinate regulation of residual bone marrow function by paracrine and epigenetic disease entities in acute myeloid leukemia and a critical assessment of their therapeutic modalities. Semin Cancer Biol. 2020;S1044-579X:30246.

25. Xie X, Feng M, Wang Q, Wang J, Yin R, Li Y, et al. Cellular and molecular state of acute myeloid leukemia stem cells. Semin Cancer Biol. 2020;S1044-579X:30246.

26. Uckelmann HJ, Kim SM, Wong EM, Hatton C, Giovinazzo H, Gadrey JY, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014;506:240–41.

27. Reikvam H, Hatfield KJ, Laisalle P, Kittang AO, Ersvaer E, Bruserud Ø. Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: Studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive angiopoietin-1 release. Expert Opin Investig Drugs. 2010;19:169–83.

28. Vukovic M, Guitart AV, Sepulveda C, Villacreces A, O’Dubbh E, Panagopoulou TI, et al. HIF-1α and HIF-2α synergize to suppress AML development but are dispensable for disease maintenance. J Exp Med. 2015;212:2223–34.

29. Feng L, Samudio J, Olise-Dwyer K, Burks JK, Mnjozan Y, Andreef M. CXX4R expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure. Blood 2020;136:398–407.

30. Borella G, Da Ros A, Borile G, Porci E, Tregnago C, Benetton M, et al. Targeting the plasticity of mesenchymal stromal cells to reroute the course of acute myeloid leukemia. Blood 2021;138:557–70.

31. Kumar B, Garcia M, Weng L, Jung X, Murakami JI, Hu X, et al. Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion. Leukemia 2018;32:575–87.

32. Huan J, Hornick NI, Goloviznina NA, Kamimae-Lanning AN, David LL, Wilmarth JL, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med. 2004;10:858–64.

33. Li L, Zhao L, Man J, Liu B. CXCL12 benefits acute myeloid leukemia cells in hypoxia. Int J Hematol 2021;103:1085–92.

34. Rao P, Sandhown L, Heshmaty Y, Kondo M, Boudlerle Y, Dolinska M, et al. Distinct roles of mesenchymal stem and progenitor cells during the development of acute myeloid leukemia in mice. Blood Adv. 2018;2:1480–94.

35. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med. 2004;10:858–64.

36. Holec PS, Zabkewicz J, Munje C, Newton Z, Paarm L, White P, et al. Overproduction of NOX-derived ROS in AML promotes proliferation and is associated with defective oxidative stress signaling. Blood 2013;122:3322–30.

37. Vetrie D, Helgason GV, Copland M. The leukaemia stem cell: Similarities, differences and clinical prospects in CML and AML. Nat Rev Cancer. 2020;20:158–73.

38. Malard T, Prata C, Viciel Dalla Sega F, Caliceti C, Zambonin L, Fiorentini D, et al. NAD(P)H oxidase isoform Nox2 plays a pro-survival role in human leukaemia stem cells. Free Radic Res. 2020;54:1111–31.

39. Chen YF, Liu H, Luo XI, Zhao Z, Zou ZY, Li J, et al. The roles of reactive oxygen species (ROS) and autophagy in the survival and death of leukemia cells. Crit Rev Oncol Hematol. 2017;112:21–30.

40. Habel B, Arnold L, Chen Y, Mollmann M, Bruderek K, Brandau S, et al. Inflammation-driven activation of JAK/STAT signaling reversibly accelerates acute myeloid leukaemia in vitro. Blood Adv. 2020;4:3000–10.

41. Demircan MB, Mgbecheta PC, Kresinsky A, Schroeder TM, Shröder K, Heidel FH, et al. Combined activity of the redox-modulating compound setanexin (GKT137831) with cytotoxic agents in the killing of acute myeloid leukemia cells. Antioxidants 2022;11:513.

42. Farge T, Saldan E, de Toni F, Aroua H, Nossenni M, Perry R, et al. Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukaemic stem cells but require oxidative metabolism. Cancer Discov. 2017;7:316–35.

43. Farge T, Saldan E, de Toni F, Aroua H, Nossenni M, Perry R, et al. Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukaemic stem cells but require oxidative metabolism. Cancer Discov. 2017;7:316–35.

44. Farge T, Saldan E, de Toni F, Aroua H, Nossenni M, Perry R, et al. Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukaemic stem cells but require oxidative metabolism. Cancer Discov. 2017;7:316–35.

45. Fiegl M, Samudio J, O’Dubbh E, Panagopoulou TI, et al. HIF-1α and HIF-2α synergize to suppress AML development but are dispensable for disease maintenance. J Exp Med. 2015;212:2223–34.

46. Vukovic M, Guitart AV, Sepulveda C, Villacreces A, O’Dubbh E, Panagopoulou TI, et al. HIF-1α and HIF-2α synergize to suppress AML development but are dispensable for disease maintenance. J Exp Med. 2015;212:2223–34.
59. Passaro D, Di Tullio A, Abarrategi A, Rouault-Pierre K, Foster K, Ariza-McNaughton L, et al. Increased vascular permeability in the bone marrow microenvironment contributes to disease progression and drug response in acute myeloid leukemia. Cancer Cell. 2017;32:324–41.e6.
60. Tabe Y, Saitoh K, Yang H, Sekharra K, Yamatani K, Ruvo1 V, et al. Inhibition of FAO in AM1 co-cultured with BM adipocytes: Mechanisms of survival and chemosensitization to cytaraibine. Sci Rep. 2018;8:16837.
61. Shafat MS, Oellerich T, Mohr S, Robinson SD, Edwards DR, Marlein CR, et al. Leukemic blast programs bone marrow adipocytes to generate a protumoral microenvironment. Blood. 2017;129:1320–32.
62. Polak R, de Rooij B, Pieters R, den Boer ML. B-cell precursor acute lymphoblastic leukemia cells use tunneling nanotubes to orchestrate their microenvironment. Blood. 2015;126:2495–8.
63. Shafat MS, Oellerich T, Mohr S, Robinson SD, Edwards DR, Marlein CR, et al. NADPH oxidase-2 derived superoxide drives mitochondrial transfer from bone marrow stromal cells to leukemic blasts. Blood. 2017;130:1649–60.
64. Hole PS, Darley RL, Tonks A. Do reactive oxygen species play a role in myeloid leukemia? Blood. 2011;117:816–26.
65. Brault J, Vigne B, Meunier M, Beaumes S, Mollin M, Park S, et al. NOX4 is the main NADPH oxidase involved in the early stages of hematopoietic differentiation from human pluripotent stem cells. Free Radic Biol Med. 2020;146:107–18.
66. Germont Z P, Sillar J R, Mannan A, et al. Blockade of redox second messengers inhibits JAK/STAT and MEK/ERK signaling sensitizing FLT3-mutant acute myeloid leukemia to targeted therapies. Preprint at bioRxiv https://doi.org/10.1101/2020.03.09.483687 (2022).
67. Demiranc MB, Mgbecheta PC, Kresinsky A, Schroeder TM, Schröder K, Heidel FH, et al. Combined activity of the redox-modulating compound setanexaz (GTK173831) with cytotoxic agents in the killing of acute myeloid leukemia cells. Antioxidants. 2022;11:513.
68. Al-Ammi HM, Irving HR, Bradley C, Meehan-Andrews T. Intrinsinc and extrinsic apoptosis responses in leukaemia cells following daunorubicin treatment. BMC Cancer. 2021;21:438.
69. Wang X, Dawod A, Nachlely M, Harrison JS, Danilenko M, Studzinski GP. Differentiation agents increase the potential AraC therapy of AML by reactivating cell death pathways without enhancing ROS generation. J Cell Physiol. 2020;235:573–86.
70. Li L, Liu W, Sun Q, Zhu H, Hong M, Qian S. Decitabine downregulates TIGAR to inhibit apoptosis and autophagy in myeloid leukemia cells. Oxid Med Cell Longev. 2021;2021:8877460.
71. Ye H, Adane B, Khan N, Sullivan T, Minjahuddin M, Gasparretto M, et al. Leukemic stem cells evade chemotherapy by metabolic adaptation to an adipose tissue niche. Cell Stem Cell. 2016;19:23–37.
72. Jones CL, Stevens BM, D’Alessandro A, Reisz JA, Culp-Hill R, Nemkov T, et al. Inhibition of amino acid metabolism selectively targets human leukemia stem cells. Cancer Cell. 2018;34:724–40.e4.
73. Polley DA, Stevens BM, Jones CL, Winters A, Pei S, Minjahuddin M, et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat Med. 2018;24:1859–66.
74. Jones CL, Stevens BM, Polley DA, Culp-Hill R, Reisz JA, Nemkov T, et al. Nicotinamide metabolism mediates resistance to venetoclax in relapsed acute myeloid leukemia stem cells. Cell Stem Cell. 2020;27:748–64.e4.
75. Stevens BM, Jones CL, Polley DA, Culp-Hill R, D’Alessandro A, Winters A, et al. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells. Nat Cancer. 2020;11:1176–87.
76. Subedi A, Liu Q, Ayyaththu DM, Sharon D, Cathelin S, Hosseini M, et al. Nicotinamide phosphoribosyltransferase inhibitors selectively induce apoptosis of AML stem cells by disrupting lipid homeostasis. Cell Stem Cell. 2021;28:1851–67.e8.
77. Chen F, Liceareta E, Wu X, Petrusca D, Maguire C, Jacobsen M, et al. Pharmacological inhibition of Carbonic Anhydrase IX and XII to enhance targeting of acute myeloid leukemia cells by disrupting lipid homeostasis. Cell Stem Cell. 2013;19:506–19.
78. Benito J, Ramirez MS, Millward NZ, Velez J, Harutyunyan KG, Lu H, et al. Hypoxia-activated prodrug TH-302 in preclinical human acute myeloid leukemia models. Clin Cancer Res. 2013;19:506–19.
79. Portwood S, Li G, Hsu YC, Vargas R, Johnson MK, Wetzler M, et al. Activity of the hypoxia-activated prodrug, TH-302, in preclinical human acute myeloid leukemia models. Clin Cancer Res. 2016;22:1687–98.
80. Papiez MA, Kryczak W. The dual effect of curcumin on etoposide action in leukemic and healthy bone marrow cells of rats with acute myeloid leukemia. Folia Med Cracov. 2014;54:71–9.
81. Papiez MA. The effect of quercetin on oxidative DNA damage and myelosuppression induced by etoposide in bone marrow cells of rats. Acta Biochim Pol. 2014;61:7–11.
82. Shah K, Mitra S, Desai U, Jain N, Rawal R. Synergism of curcumin and cytaraibine in the down regulation of multi-drug resistance genes in acute myeloid leukemia. Anticancer Agents Med Chem. 2016;16:128–35.
83. Naimi A, Entezari A, Hagh MF, Hassanzadeh A, Saeaei R, Solali S. Quercetin sensitizes human myeloid leukemia KG-1 cells against TRAIL-induced apoptosis. J Cell Physiol. 2019;234:13233–41.
106. Wang J, He N, Wang R, Tian T, Han F, Zhong C, et al. Analysis of TET2 and EZH2 gene functions in chromosome instability in acute myeloid leukemia. Sci Rep. 2020;10:2706.

107. Wright RL, Vaughan AT. A systematic description of MLL fusion gene formation. Crit Rev Oncol Hematol. 2014;91:283–91.

108. Pastore F, Levine RL. Epigenetic regulators and their impact on therapy in acute myeloid leukemia. Haematologica 2016;101:269–78.

109. Adema V, Colla S. EZH2 inhibitors: The unpacking revolution. Cancer Res. 2022;82:359–61.

110. Lamble AJ, Gerbing RB, Smith JL, Ries RE, Kolb EA, Alonzo TA, et al. Crebbp alterations are associated with a poor prognosis in De Novo AML. Blood 2021;138:3451.

111. Gutierrez SE, Romero-Oliva FA. Epigenetic changes: A common theme in acute myelogenous leukemogenesis. J Hematol Oncol. 2013;6:57.

112. Castelli G, Pelosi E, Testa U. Targeting histone methyltransferase and demethylase in acute myeloid leukemia therapy. Onco Targets Ther. 2017;11:131–55.

113. San José-Enériz E, Gimenez-Camino N, Agirre X, Prosper F. HDAC inhibitors in acute myeloid leukemia. Cancers 2019;11:1794.

114. Ceccacci E, Minucci S. Inhibition of histone deacetylases in cancer therapy: Lessons from leukaemia. Br J Cancer. 2016;114:605–11.

115. Wang L, Birch NW, Zhao Z, Nestler CM, Kazmer A, Shilati A, et al. Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemia. Nat Cancer. 2021;2:515–26.

ACKNOWLEDGEMENTS
This research was supported by the scientific research project of the Sichuan Province Education Department (No. 162A0241), the National Natural Science Foundation of China [82060268], and the Guangxi Natural Science Foundation of China [2020JJA140124].

AUTHOR CONTRIBUTIONS
Conceptualization, YC and JL; writing—original draft preparation, YC and JL; writing—review and editing, LX, ZZ, and M-AG; prepared figures: YC and JL; supervision, YC and M-AG. All authors have read and agreed to the published version of the manuscript.

COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Correspondence and requests for materials should be addressed to Yongfeng Chen, Mihnea-Alexandru Găman or Zhenyou Zou.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022